Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Zeluvalimab by Amgen for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
Zeluvalimab is under clinical development by Amgen and currently in Phase I for Esophageal Squamous Cell Carcinoma (ESCC). According to...
Zeluvalimab by Amgen for Merkel Cell Carcinoma: Likelihood of Approval
Zeluvalimab is under clinical development by Amgen and currently in Phase I for Merkel Cell Carcinoma. According to GlobalData, Phase...
Zeluvalimab by Amgen for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Zeluvalimab is under clinical development by Amgen and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC)....
Zeluvalimab by Amgen for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
Zeluvalimab is under clinical development by Amgen and currently in Phase I for Metastatic Transitional (Urothelial) Tract Cancer. According to...
Zeluvalimab by Amgen for Metastatic Renal Cell Carcinoma: Likelihood of Approval
Zeluvalimab is under clinical development by Amgen and currently in Phase I for Metastatic Renal Cell Carcinoma. According to GlobalData,...
Zeluvalimab by Amgen for Thymic Carcinoma: Likelihood of Approval
Zeluvalimab is under clinical development by Amgen and currently in Phase I for Thymic Carcinoma. According to GlobalData, Phase I...
Zeluvalimab by Amgen for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Zeluvalimab is under clinical development by Amgen and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According to...
Zeluvalimab by Amgen for Skin Cancer: Likelihood of Approval
Zeluvalimab is under clinical development by Amgen and currently in Phase I for Skin Cancer. According to GlobalData, Phase I...
Zeluvalimab by Amgen for Nasopharyngeal Cancer: Likelihood of Approval
Zeluvalimab is under clinical development by Amgen and currently in Phase I for Nasopharyngeal Cancer. According to GlobalData, Phase I...
Zeluvalimab by Amgen for Non-Small Cell Lung Cancer: Likelihood of Approval
Zeluvalimab is under clinical development by Amgen and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData,...
Zeluvalimab by Amgen for Metastatic Melanoma: Likelihood of Approval
Zeluvalimab is under clinical development by Amgen and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase I...
Zeluvalimab by Amgen for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Zeluvalimab is under clinical development by Amgen and currently in Phase I for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData,...
Zeluvalimab by Amgen for Gastric Cancer: Likelihood of Approval
Zeluvalimab is under clinical development by Amgen and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...
Zeluvalimab by Amgen for Cervical Cancer: Likelihood of Approval
Zeluvalimab is under clinical development by Amgen and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I...